SGIO.F Stock Overview
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 5/6 |
Shionogi & Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥49.60 |
52 Week High | JP¥53.50 |
52 Week Low | JP¥40.46 |
Beta | 0.36 |
1 Month Change | -7.29% |
3 Month Change | n/a |
1 Year Change | 9.88% |
3 Year Change | -4.71% |
5 Year Change | -12.98% |
Change since IPO | 270.15% |
Recent News & Updates
Recent updates
Shareholder Returns
SGIO.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | -3.2% | -3.5% |
1Y | 9.9% | 11.7% | 20.2% |
Return vs Industry: SGIO.F underperformed the US Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: SGIO.F underperformed the US Market which returned 20.2% over the past year.
Price Volatility
SGIO.F volatility | |
---|---|
SGIO.F Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SGIO.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SGIO.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1878 | 5,680 | Isao Teshirogi | www.shionogi.com |
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19.
Shionogi & Co., Ltd. Fundamentals Summary
SGIO.F fundamental statistics | |
---|---|
Market cap | US$13.25b |
Earnings (TTM) | US$998.76m |
Revenue (TTM) | US$2.75b |
13.0x
P/E Ratio4.7x
P/S RatioIs SGIO.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SGIO.F income statement (TTM) | |
---|---|
Revenue | JP¥425.16b |
Cost of Revenue | JP¥60.08b |
Gross Profit | JP¥365.08b |
Other Expenses | JP¥210.62b |
Earnings | JP¥154.46b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 13, 2024
Earnings per share (EPS) | 544.84 |
Gross Margin | 85.87% |
Net Profit Margin | 36.33% |
Debt/Equity Ratio | 0% |
How did SGIO.F perform over the long term?
See historical performance and comparison